×
About 6,655 results

ALLMedicine™ Peripheral Neuropathy Center

Research & Reviews  2,997 results

A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART...
https://doi.org/10.1007/s00280-020-04135-8
Cancer Chemotherapy and Pharmacology; Kotaka M, Saito Y et. al.

Sep 23rd, 2020 - The purpose of this clinical study was to be the first to explore whether ART-123, a recombinant human soluble thrombomodulin, prevents oxaliplatin-induced peripheral neuropathy (OIPN). This randomized, phase IIa trial enrolled stage II/III colon ...

Sexual dimorphism in the contribution of neuroendocrine stress axes to oxaliplatin-indu...
https://doi.org/10.1097/j.pain.0000000000002073
Pain Staurengo-Ferrari L, Green PG et. al.

Sep 18th, 2020 - While clinical studies support the suggestion that stress is a risk factor for painful chemotherapy-induced peripheral neuropathy (CIPN), there is little scientific validation to support this link. Here, we evaluated the impact of stress on CIPN i...

Characteristics of the intestinal flora in patients with peripheral neuropathy associat...
https://doi.org/10.1177/0300060520936806
The Journal of International Medical Research; Wang Y, Ye X et. al.

Sep 17th, 2020 - To study the characteristics of the intestinal flora in patients with diabetic peripheral neuropathy (DPN) and analyze the association between the intestinal flora and clinical indicators. We classified 80 subjects into three groups: patients with...

PINK1 alleviates thermal hypersensitivity in a paclitaxel-induced Drosophila model of p...
https://doi.org/10.1371/journal.pone.0239126
PloS One; Kim YY, Yoon JH et. al.

Sep 17th, 2020 - Paclitaxel is a representative anticancer drug that induces chemotherapy-induced peripheral neuropathy (CIPN), a common side effect that limits many anticancer chemotherapies. Although PINK1, a key mediator of mitochondrial quality control, has be...

A Review on Mechanistic and pharmacological findings of Diabetic Peripheral Neuropathy ...
https://doi.org/10.2174/1573399816666200914141558
Current Diabetes Reviews; Tiwari R, Wal P et. al.

Sep 15th, 2020 - Chronic hyperglycaemia and related complications involving peripheral nerves in diabetes are one of the most severe microvascular complications with an average prevalence of 50-60%. Diabetic neuropathy is among the vascular disorders of diabetes, ...

see more →

Guidelines  2 results

Treatment of peripheral arterial disease in diabetes: a consensus of the Italian Societ...
https://doi.org/10.1016/j.numecd.2013.12.007
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD; Aiello A, Anichini R et. al.

Feb 3rd, 2014 - Diabetic foot (DF) is a chronic and highly disabling complication of diabetes. The prevalence of peripheral arterial disease (PAD) is high in diabetic patients and, associated or not with peripheral neuropathy (PN), can be found in 50% of cases of...

Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessm...
https://doi.org/10.1002/dmrr.1225
Diabetes/metabolism Research and Reviews; Tesfaye S, Vileikyte L et. al.

Jun 22nd, 2011 - Painful diabetic peripheral neuropathy (DPN) is common, is associated with significant reduction in quality of life and poses major treatment challenges to the practising physician. Although poor glucose control and cardiovascular risk factors hav...

see more →

Drugs  291 results see all →

Clinicaltrials.gov  3,315 results

A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART...
https://doi.org/10.1007/s00280-020-04135-8
Cancer Chemotherapy and Pharmacology; Kotaka M, Saito Y et. al.

Sep 23rd, 2020 - The purpose of this clinical study was to be the first to explore whether ART-123, a recombinant human soluble thrombomodulin, prevents oxaliplatin-induced peripheral neuropathy (OIPN). This randomized, phase IIa trial enrolled stage II/III colon ...

Duloxetine - duloxetine capsule, delayed release-AvPAK
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afd46d7e-0257-1bd0-e053-2a95a90a0722

Sep 20th, 2020 - Duloxetine delayed-release capsules are indicated for the treatment of: • Major Depressive Disorder [see Clinical Studies ( 14.1)] • Generalized Anxiety Disorder [see Clinical Studies ( 14.2)] • Diabetic Peripheral Neuropathy [see Clinical Studies...

Sexual dimorphism in the contribution of neuroendocrine stress axes to oxaliplatin-indu...
https://doi.org/10.1097/j.pain.0000000000002073
Pain Staurengo-Ferrari L, Green PG et. al.

Sep 18th, 2020 - While clinical studies support the suggestion that stress is a risk factor for painful chemotherapy-induced peripheral neuropathy (CIPN), there is little scientific validation to support this link. Here, we evaluated the impact of stress on CIPN i...

Characteristics of the intestinal flora in patients with peripheral neuropathy associat...
https://doi.org/10.1177/0300060520936806
The Journal of International Medical Research; Wang Y, Ye X et. al.

Sep 17th, 2020 - To study the characteristics of the intestinal flora in patients with diabetic peripheral neuropathy (DPN) and analyze the association between the intestinal flora and clinical indicators. We classified 80 subjects into three groups: patients with...

PINK1 alleviates thermal hypersensitivity in a paclitaxel-induced Drosophila model of p...
https://doi.org/10.1371/journal.pone.0239126
PloS One; Kim YY, Yoon JH et. al.

Sep 17th, 2020 - Paclitaxel is a representative anticancer drug that induces chemotherapy-induced peripheral neuropathy (CIPN), a common side effect that limits many anticancer chemotherapies. Although PINK1, a key mediator of mitochondrial quality control, has be...

see more →

News  45 results

Effectiveness of duloxetine in treatment of painful chemotherapy-induced peripheral neuropathy: a systematic review
https://www.mdedge.com/hematology-oncology/article/190462/patient-survivor-care/effectiveness-duloxetine-treatment-painful?channel=270
Ibrahim et al

Dec 6th, 2018 - Chemotherapy-induced peripheral neuropathy (CIPN) is a serious side effect that can be dose limiting and affect patient quality of life for prolonged time,1 with an overall incidence of about 38% in patients who are treated with multiple chemother.

Drug may alleviate CIPN in MM patients
https://www.mdedge.com/hematology-oncology/article/184977/multiple-myeloma/drug-may-alleviate-cipn-mm-patients
HT Staff

May 2nd, 2018 - Photo from Business Wire Bortezomib Researchers say they’ve discovered why multiple myeloma (MM) patients may experience chemotherapy-induced peripheral neuropathy (CIPN) when treated with bortezomib. The group’s study also suggests fingolimod—a d.

Cryotherapy can reduce signs of CIPN
https://www.mdedge.com/hematology-oncology/article/185364/leukemia-myelodysplasia-transplantation/cryotherapy-can-reduce-signs-cipn
HT Staff

Oct 14th, 2017 - Photo by Rhoda Baer Nurse bandaging chemotherapy patient A new study suggests cryotherapy can reduce symptoms of chemotherapy-induced peripheral neuropathy (CIPN). Researchers found that having chemotherapy patients wear frozen gloves and socks fo.

Cryotherapy May Help Prevent Neuropathy in Cancer Patients
https://www.medpagetoday.com/hematologyoncology/chemotherapy/68498

Oct 12th, 2017 - Action Points The use of cryotherapy can help prevent chemotherapy-induced peripheral neuropathy (CIPN) in cancer patients. Note that duloxetine (Cymbalta) has been recommended for CIPN, but it has limited efficacy for chemotherapy-induced pain, a...

Chemo-Related Neuropathy Poses Safety, QoL Risks
https://www.medpagetoday.com/hematologyoncology/breastcancer/67301

Aug 15th, 2017 - Action Points Almost half of female long-term cancer survivors had persistent symptoms of chemotherapy-induced peripheral neuropathy (CIPN) that affected physical function. Note that the study suggests that CIPN must be assessed earlier in the cli...

see more →

Patient Education  5 results see all →